Related Experiment Video
Updated: Aug 30, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
5-ALA Is a Potent Lactate Dehydrogenase Inhibitor but Not a Substrate: Implications for Cell Glycolysis and New
Mantas Grigalavicius1, Somayeh Ezzatpanah1, Athanasios Papakyriakou2
1Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, 0379 Oslo, Norway.
Abstract:
In a course of metabolic experiments, we determined that the addition of δ-aminolevulinic acid (5-ALA) to a panel of glioblastoma multiforme (GBM) cells caused a steep reduction in their glycolytic activity. This reduction was accompanied by a decrease in adenosine triphosphate (ATP) production from glycolysis. These results suggested that 5-ALA is an inhibitor of glycolysis; due to the structural similarity of 5-ALA to the established lactate dehydrogenase (LDH) inhibitors oxamate (OXM) and tartronate (TART), we initially investigated LDH inhibition by 5-ALA in silico. The modelling revealed that 5-ALA could indeed be a competitive inhibitor of LDH but not a substrate. These theoretical findings were corroborated by enzymatic and cell lysate assays in which 5-ALA was found to confer a potent LDH inhibition comparable to that of OXM and TART. We subsequently evaluated the effect of 5-ALA-induced glycolysis inhibition on the viability of GBM cells with diverse metabolic phenotypes. In the Warburg-type cell lines Ln18 and U87, incubation with 5-ALA elicited profound and irreversible cell death (90-98%) at 10 mM after merely 24 h. In T98G, however, which exhibited both high respiratory and glycolytic rates, LD95 was achieved after 72 h of incubation with 20 mM 5-ALA. We additionally examined the production of the 5-ALA photosensitive metadrug protoporphyrin IX (PpIX), with and without prior LDH inhibition by TART. These studies revealed that ~20% of the 5-ALA taken up by the cells was engaged in LDH inhibition. We subsequently performed 5-ALA photodynamic therapy (PDT) on Ln18 GBM cells, again with and without prior LDH inhibition with TART, and found a PDT outcome enhancement of ~15% upon LDH pre-inhibition. We expect our findings to have a profound impact on contemporary oncology, particularly for the treatment of otherwise incurable brain cancers such as GBM, where the specific accumulation of 5-ALA is very high compared to the surrounding normal tissue.
Insights
δ-aminolevulinic acid (5-ALA) effectively inhibits glioblastoma cell glycolysis and lactate dehydrogenase (LDH), leading to significant cell death. This discovery offers a promising new avenue for treating aggressive brain cancers like GBM.
Area of Science:
- Biochemistry
- Oncology
- Metabolic pathways
Background:
- Glioblastoma multiforme (GBM) exhibits high glycolytic activity, a key metabolic vulnerability.
- δ-aminolevulinic acid (5-ALA) is known to accumulate in GBM cells.
- Lactate dehydrogenase (LDH) plays a crucial role in glycolysis.
Purpose of the Study:
- To investigate the effect of 5-ALA on GBM cell glycolysis and viability.
- To determine if 5-ALA inhibits LDH.
- To evaluate the potential of 5-ALA as a therapeutic agent for GBM.
Main Methods:
- In silico modeling to assess 5-ALA's interaction with LDH.
- Enzymatic and cell lysate assays to confirm LDH inhibition.
- Cell viability assays on various GBM cell lines treated with 5-ALA.
- Protoporphyrin IX (PpIX) production and photodynamic therapy (PDT) experiments.
Main Results:
- 5-ALA significantly reduced glycolytic activity and ATP production in GBM cells.
- 5-ALA was confirmed as a potent, competitive inhibitor of LDH.
- Incubation with 5-ALA induced profound and irreversible cell death in GBM cell lines (90-98% at 10 mM within 24 h).
- LDH inhibition by 5-ALA enhanced the efficacy of 5-ALA-based photodynamic therapy by approximately 15%.
Conclusions:
- 5-ALA acts as a potent inhibitor of glycolysis and LDH in glioblastoma cells.
- 5-ALA demonstrates significant anti-cancer activity against GBM, inducing substantial cell death.
- Combining 5-ALA with PDT, particularly with prior LDH inhibition, enhances therapeutic outcomes.
- These findings present 5-ALA as a promising therapeutic candidate for glioblastoma treatment.
Related Concept Videos
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Drugs that Destabilize Microtubules
Drugs that Stabilize Microtubules
Drugs for Treatment of Ulcerative Colitis in IBD
Targeted Cancer Therapies
There are several types of targeted therapies against...

